• Duphat
  • infinia camp
mededge mea logo web MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
    • ME Explained
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share
Notification
  • Duphat
  • infinia camp
mededge mea logo web
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
    • ME Explained
Have an existing account? Sign In
MedEdge MEA > Resource Hub > Personnel > Novo Nordisk announces key executive management changes effective April 2025
Personnel

Novo Nordisk announces key executive management changes effective April 2025

ME Desk
ME Desk
Published: April 12, 2025
Share
2 Min Read
SHARE

Bagsvรฆrd, Denmark- April 2025– Novo Nordisk announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company. Consequently, as of 3 April 2025, the following organisational changes are implemented:

Ludovic Helfgott, executive vice president, Rare Disease, will assume the responsibility for Product & Portfolio Strategy, including commercial strategy, medical affairs and business development across all therapy areas. Ludovic joined Novo Nordisk in 2019 as executive vice president and has led the establishment of a strategic Rare Disease portfolio. Before joining Novo Nordisk, Ludovic was responsible for the cardiovascular, metabolic and renal portfolios at AstraZeneca.

Thilde Hummel Bรธgebjerg, senior vice president, Product Supply Emerging Technologies, is promoted to executive vice president, Quality, IT & Environmental Affairs. Thilde has been with Novo Nordisk for 18 years and has held various leadership roles with increasing responsibility, mainly within Product Supply and CMC development. Thilde is a Danish national based in Denmark.

Also Read : CagriSema shows promise in Novo Nordiskโ€™s phase 3 obesity trial

Lastly, Tania Sabroe, executive vice president of People & Organisation, assumes responsibility for Global Communication in addition to her current responsibilities.

With these changes, Executive Management will have the following members as of 3 April 2025:

  • Lars Fruergaard Jรธrgensen, president and CEO*
  • Thilde Hummel Bรธgebjerg, EVP, Quality, IT & Environmental Affairs
  • Maziar Mike Doustdar, EVP, International Operations
  • Ludovic Helfgott, EVP, Product & Portfolio Strategy
  • Karsten Munk Knudsen, EVP, chief financial officer*
  • Martin Holst Lange, EVP, Development
  • Dave Moore, EVP,ย USย Operations
  • Tania Sabroe, EVP, People, Organisation and Communication
  • Marcus Schindler, EVP, chief scientific officer, Research & Early Development
  • Henrik Wulff, EVP, Product Supply

* Registered as an executive with the Danish Business Authority.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article immune system Boost immune system: Stay strong with five foods that enhance your immunity.
Next Article RINVOQ European Commission approves AbbVieโ€™s RINVOQยฎ for treatment of Giant Cell Arteritis

Recent Posts

  • From market access to national ambition, gulf healthcare is playing a longer game
  • New Push for HIV Innovation and Access Aims to Accelerate Progress Toward 2030 Goals
  • WHO Discusses Digital Health and Humanization of Care at Scientific Conference
  • Rising Ebola Cases Deepen Humanitarian Crisis for Children in DR Congo
  • Burjeel holdings secures dual credit ratings and launches USD 1.5 billion sukuk programme
  • duphat
  • MedEdge-Infinia
Two Point Five Logo white
  • About Us
  • Contact Us
  • Medical Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Cookie Policy (EU)
  • Submit Your Story
  • MediaKit
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share

Published by Two Point Five Media FZCO

  • About Us
  • Contact Us
  • Medical Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Cookie Policy (EU)
  • Submit Your Story
  • MediaKit
Reading: Novo Nordisk announces key executive management changes effective April 2025
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}

WhatsApp us

Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?